EUVIMEDEUVIMED entdecken
Übersichtsarbeit

PET Molecular Imaging and Theranostics in Lung Diseases

Majid Assadi, Malik E Juweid, Danny D Jonigk, Jan Spillner, Yaser M Rayyan, Hajer Jarraya, Felix M Mottaghy, Raed A Dweik

CHEST · 2026-10 · 170 (4) · 1187-1199

DOI: 10.1016/j.chest.2026.03.025 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CHEST, 2026-10. Verfasst von Majid Assadi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Persian Gulf Nuclear Medicine Research Center, The Persian Gulf Biomedical Research Institute, Department of Nuclear Medicine, Molecular Imaging, and…. Hauptthemen laut MEDLINE: Precision Medicine, Molecular Imaging, Lung Diseases, Positron-Emission Tomography. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TOPIC IMPORTANCE: The integration of molecular and anatomic imaging-particularly via modalities such as PET/CT scan, PET/MRI scan, and emerging total-body PET scan-has significantly advanced the detection, characterization, and personalized treatment of both oncological and nononcological pulmonary diseases. REVIEW FINDINGS: In oncology, 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG) PET/CT scan remains the cornerstone for lung cancer staging and therapeutic monitoring. New radiotracers targeting amino acid metabolism, receptor expression, angiogenesis, and hypoxia enable earlier and more reliable assessment of cell status. Immuno-PET scan and fibroblast activation protein inhibitor (FAPI) PET scan improve lesion detection and treatment stratification, particularly where 18FDG-PET is limited. These innovations support accurate staging and dynamic treatment response monitoring. Theranostics, where diagnostic molecules confer therapeutic potential, has gained attention for lung neuroendocrine tumors and potentially other tumors. For example, the theranostics pair Gallium-68-DOTATATE and 177Lu-DOTATATE allow detection and treatment with the same targeting ligand. Beyond oncology, molecular imaging is promising for nononcological lung diseases, particularly interstitial lung diseases. For example, radiolabeled FAPI tracers could noninvasively quantify fibroblast activity, aiding in disease assessment, therapy guidance, and prognosis. Dual-tracer approaches, such as 18FDG-PET scan and FAPI PET scan, further may refine differentiation between inflammatory and fibrotic components of disease. SUMMARY: Molecular imaging has revolutionized the management of lung disease, allowing earlier detection, more accurate diagnosis, and the advancement of precision medicine. Looking ahead, the future of molecular imaging lies in developing multitracer protocols for comprehensive assessment. In this way, imaging not only informs diagnosis but also guides targeted therapy (theranostics), ultimately supporting the optimization of individualized patient care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineMolecular ImagingLung DiseasesPositron-Emission TomographyTheranostic NanomedicineHumansRadiopharmaceuticalsPositron Emission Tomography Computed TomographyLung NeoplasmsFluorodeoxyglucose F18

Stichwörter der Autor:innen

PET scanfibroblast activation proteinlungmolecular imagingprecision medicinetheranostics

Substanzen

RadiopharmaceuticalsFluorodeoxyglucose F18

Autor:innen und Institutionen

  • Persian Gulf Nuclear Medicine Research Center, The Persian Gulf Biomedical Research Institute, Department of Nuclear Medicine, Molecular Imaging, and Theranostics, Bushehr Medical University Hospital, School of Medicine…
  • Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University of Jordan, Amman, Jordan; National Center for Diabetes, Endocrinology, and Genetics, University of Jordan, Amman, Jordan. Electronic…
  • Institute of Pathology, Uniklinik RWTH Aachen, Aachen, Germany; Centre for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Aachen, Germany; German Center for Lung Research, DZL, BREATH, Hanover, Germany.
  • Department of Thoracic Surgery, University Hospital RWTH Aachen, Aachen, Germany.
  • School of Medicine, The University of Jordan, Amman, Jordan.
  • Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Zitieren

APA

Assadi, M., Juweid, M. E., Jonigk, D. D., Spillner, J., Rayyan, Y. M., Jarraya, H., Mottaghy, F. M., & Dweik, R. A. (2026). PET Molecular Imaging and Theranostics in Lung Diseases. CHEST, 170(4), 1187-1199. https://doi.org/10.1016/j.chest.2026.03.025

Vancouver

Assadi M, Juweid ME, Jonigk DD, Spillner J, Rayyan YM, Jarraya H, et al. PET Molecular Imaging and Theranostics in Lung Diseases. CHEST. 2026;170(4):1187-1199. doi:10.1016/j.chest.2026.03.025

BibTeX
@article{Assadi2026,
  author = {Assadi, Majid and Juweid, Malik E and Jonigk, Danny D and Spillner, Jan and Rayyan, Yaser M and Jarraya, Hajer and Mottaghy, Felix M and Dweik, Raed A},
  title = {PET Molecular Imaging and Theranostics in Lung Diseases},
  journal = {CHEST},
  year = {2026},
  volume = {170},
  number = {4},
  pages = {1187--1199},
  doi = {10.1016/j.chest.2026.03.025}
}
Kostenlos starten →